logo

Rexahn Pharmaceuticals Inc. (RNN)



Trade RNN now with
  Date
  Headline
11/5/2018 8:09:38 AM Rexahn Q3 Net Loss $5.3 Mln Or $0.17/Shr Vs Net Loss $1.0 Mln Or $0.04/Shr Last Year
10/17/2018 9:04:07 AM Rexahn Plans $7.5 Mln Registered Direct Offering
8/21/2018 8:06:45 AM Rexahn Enters Clinical Trial Collaboration Agreement With Merck To Evaluate RX-5902 In Combination With KEYTRUDA
8/6/2018 8:12:39 AM Rexahn Pharma Q2 Net Loss $3.8 Mln Or $0.12/Shr Vs Income Of $0.9 Mln Or $0.04/Shr Last Year
6/14/2018 10:01:14 AM Rexahn Announces Adjournment Of AGM Until June 27, 2018
6/4/2018 8:10:50 AM Rexahn Pharma Says Preliminary Data From Phase 2a Clinical Trial Of RX-5902; Updated Data From Phase 2a Trial Of RX-3117
5/7/2018 8:10:56 AM Rexahn Q1 Loss Per Share $0.07 Vs Loss $0.91 Last Year
3/12/2018 8:09:13 AM Rexahn Pharma FY Net Loss $25.3 Mln Or $0.92/Shr Vs Loss Of $9.3 Mln Or $0.43/Shr Last Year
2/12/2018 8:15:30 AM Rexahn Reports Data From Ongoing Phase 2a Clinical Trial Of RX-3117 In Advanced Bladder Cancer At ASCO GU
2/8/2018 8:12:57 AM Rexahn Pharma Unveils Collaboration With Zhejiang Haichang For Development Of RX-0201 For Hepatocellular Carcinoma
1/29/2018 8:10:35 AM Rexahn Receives Notice Of Allowance For New U.S. Patent Covering The Use Of RX-5902 (Supinoxin)
1/22/2018 7:32:29 AM Rexahn Pharma Announces Poster Presentation Of RX-3117 Data In Metastatic Pancreatic Patients
1/4/2018 9:04:36 AM Rexahn Pharma Names Douglas Swirsky President And CFO